Aeterna Zentaris Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin
November 16, 2020 08:05 ET
|
Aeterna Zentaris Inc
- Company to receive upfront payment of €5 million replacing a later stage regulatory approval milestone of U.S.$5 million - Novo Nordisk committing to fund €9 million of the budgeted AEZS-130-P02...
Aeterna Zentaris Reports Third Quarter 2020 Financial Results and Provides Business Update
November 06, 2020 08:35 ET
|
Aeterna Zentaris Inc
– Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q1 2021 – Continue to advance discussions to secure a commercialization partner for macimorelin in...
Aeterna Zentaris Announced Presentation of Positive Results from First Pediatric Study of Macimorelin at the 22nd European Congress of Endocrinology
September 08, 2020 08:05 ET
|
Aeterna Zentaris Inc
- PK and PD profiles of macimorelin for pediatric use were within the expected range and comparable to results observed in adults - - Data from this study support the choice of 1.0 mg/kg dose of...
Aeterna Zentaris Reports Second Quarter 2020 Financial Results and Provides Business Update
August 06, 2020 08:35 ET
|
Aeterna Zentaris Inc
– Positive results from AEZS-130-P01 (“Study P01”) confirmed dosing regimen of macimorelin as a potential diagnostic for childhood-onset growth hormone deficiency – Safety and efficacy...
Aeterna Zentaris Announces Continued Expansion of Intellectual Property Portfolio for Macimorelin with Additional Patent Applications
July 31, 2020 07:35 ET
|
Aeterna Zentaris Inc
CHARLESTON, S.C., July 31, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing
July 29, 2020 07:05 ET
|
Aeterna Zentaris Inc
CHARLESTON, S.C., July 29, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company commercializing and...
AETERNA ZENTARIS ANNOUNCES DISTRIBUTION AGREEMENT WITH MEGAPHARM LTD. TO COMMERCIALIZE MACIMORELIN IN ISRAEL AND THE PALESTINE AUTHORITY
June 25, 2020 08:00 ET
|
Aeterna Zentaris Inc
CHARLESTON, S.C, June 25, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing...